Wake Research-Clinical Research Center of Nevada was selected by Moderna to participate in the pivotal Phase 3 clinical trial evaluating their advanced COVID-19 vaccine candidate known as mRNA-1273. The race to stop COVID-19 comes to Las Vegas—the nation’s entertainment capital needs a cure and fast.
Threat of Economic Devastation
The COVID-19 pandemic has created an imminent threat to devastate the Las Vegas economy, which is highly dependent on tourism and entertainment-focused travel. According to some reports, Las Vegas will be most of the most severely impacted urban areas from this global public health crisis.
For example, Nevada more than any other state relies on tourism and this is primarily driven by the wide variety of entertainment and resort choices Las Vegas has to offer. In an average year ,the city can attract about 42 million tourists. The implications of COVID-19 and shutdowns, quarantines and social distancing are economically grave. Prior to the pandemic, the city could count on 3.5 million people visiting per month; this went to zero, which represents a staggering series of losses. Businesses throughout Las Vegas face a highly uncertain future: only those with the capital and resources to withstand this pandemic can survive.
And think of the implications for employees. Las Vegas has been a place where the average worker, one without an advanced degree, could easily secure a decently paying job and buy a home and experience a piece of the American Dream. Long ago, much of Northern and Southern California became too expensive. Hence Las Vegas represented a place to achieve more for those that didn’t have the connections, or education or whatever else is needed in coastal California. Now if this pathogen isn’t under control soon, many employees, out of work, will be in a dire situation.
The Vaccine Trial Requires Heroes
Now, Wake Research-Clinical Research Center, operating in a prime testing ground, seeks volunteers for the study. The clinical trial needs lots of participation from those individuals that face higher risk, such as essential workers that either cater to the tourists that are now visiting again, to health care workers, first responders, etc. The study for this still is led by principal investigator Dr. Michael Levin, who commented, “We have many, many more essential workers in different fields say than other places.”
The team is looking for participants, over the age of 18 with or without health issues, reports NBC 3 News in Las Vegas. As is with all other Moderna mRNA-1273 vaccine trial sites, the teams will monitor the volunteers for up to two years. Dr. Levin reported to the local press that they’ll be monitoring the patients closely for any symptoms. He hopes the study can commence by the first week of August if not a little sooner. Some sites involved with this study have forecast July 27.
The Jackpot moment, according to Dr. Levin: “If the numbers look like only the people who got COVID were the placebo patients. Bingo, you have a very effective vaccine.
Dr. Levin emphasizes that those volunteering and participating in this historic trial can be called heroes. This is how medical advancements occur, and in the case of COVID-19, the future of the Las Vegas economy could be at stake as well.
The Research Site
Clinical Research Center of Nevada (CCRC) is a research site firm based in Las Vegas, Nevada. The site operation has been conducting clinical trials in the Las Vegas area for over 16 years. With multiple sites, therapeutic areas and trained staff, they emphasize a patient-centered, safe and friendly environment. CRCN is part of the Wake Research Network. The site’s operations are run by Darlene G. Steljes, RRT, RPSGT, CCRC. For a summary of the diverse actual facilities supporting this research site operation, follow the link.
Wake Research Network
Wake Research is an organization of integrated investigational sites, committed to excellence, working closely with and meeting the needs of biopharmaceutical, biotechnology, medical device and pharmaceutical industries. These sites are fully equipped to meet the needs of sponsors and CROs in the conduct of Phase I-IV clinical trials in a wide variety of indications.
Wake Research has conducted over 5,900 research studies for hundreds of pharmaceutical sponsors and CROs since its inception in 1984.
Call to Action: Note that volunteers will be compensated for their time and travel. The initial evaluation could take an hour or two according to Dr. Levin. A mask must be worn; temperature and vitals will be checked, along with medical history, before the vaccine is administered. Contact CRCN for more details with a text at (702) 357-9659 or visit here.